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The primary circulating form of vitamin D, 25-hydroxy-vitamin D [25(OH)D], is associated with multiple medi-
cal outcomes, including rickets, osteoporosis, multiple sclerosis and cancer. In a genome-wide association
study (GWAS) of 4501 persons of European ancestry drawn from ﬁve cohorts, we identiﬁed single-nucleotide
polymorphisms (SNPs) in the gene encoding group-speciﬁc component (vitamin D binding) protein, GC,o n
chromosome 4q12-13 that were associated with 25(OH)D concentrations: rs2282679 (P 5 2.0 3 10
230), in link-
age disequilibrium (LD) with rs7041, a non-synonymous SNP (D432E; P 5 4.1 3 10
222) and rs1155563 (P 5
3.8 3 10
225). Suggestive signals for association with 25(OH)D were also observed for SNPs in or near
three other genes involved in vitamin D synthesis or activation: rs3829251 on chromosome 11q13.4 in
NADSYN1 [encoding nicotinamide adenine dinucleotide (NAD) synthetase; P 5 8.8 3 10
27], which was in
high LD with rs1790349, located in DHCR7, the gene encoding 7-dehydrocholesterol reductase that syn-
thesizes cholesterol from 7-dehydrocholesterol; rs6599638 in the region harboring the open-reading frame
88 (C10orf88) on chromosome 10q26.13 in the vicinity of ACADSB (acyl-Coenzyme A dehydrogenase),
involved in cholesterol and vitamin D synthesis (P 5 3.3 3 10
27); and rs2060793 on chromosome 11p15.2
in CYP2R1 (cytochrome P450, family 2, subfamily R, polypeptide 1, encoding a key C-25 hydroxylase that con-
verts vitamin D3 to an active vitamin D receptor ligand; P 5 1.4 3 10
25). We genotyped SNPs in these four
regions in 2221 additional samples and conﬁrmed strong genome-wide signiﬁcant associations with
25(OH)D through meta-analysis with the GWAS data for GC (P 5 1.8 3 10
249), NADSYN1/DHCR7 (P 5 3.4 3
10
29) and CYP2R1 (P 5 2.9 3 10
217), but not C10orf88 (P 5 2.4 3 10
25).
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TheprimaryformofcirculatingvitaminD,25-hydroxy-vitamin
D [25(OH)D], is a modiﬁable quantitative trait associated with
multiple medical outcomes, including osteoporosis, multiple
sclerosis, selected malignancies, and especially colorectal
cancer, with rickets being the most common expression of
severe clinical vitamin D deﬁciency in children (1). The con-
centration of 25(OH)D in blood, which reﬂects endogenous
generation through ultraviolet B (UVB) exposure as well as
exogenous dietary and supplemental vitamin D intake, is con-
sidered the best indicator of vitamin D status. Following meta-
bolic activation to 1,25-dihydroxy-vitamin D [1,25(OH)2D]
through multiple hydroxylation steps (2), vitamin D has
pleiotropic effects in addition to its traditional role in calcium
homeostasis; for example, vitamin D receptor response
elements directly or indirectly inﬂuence cell cycling and
proliferation, differentiation and apoptosis (3).
Common genetic variants that inﬂuence circulating
25(OH)D levels could be important for identifying persons
at risk for vitamin D deﬁciency and enhancing our understand-
ing of the observed associations between vitamin D status and
several diseases. Previously, twin studies suggested a heritable
component to circulating vitamin D levels (4–6), and investi-
gations of common genetic variation in candidate genes in
relation to 25(OH)D concentrations have been based on
small study samples and were inconclusive. Here, we report
an analysis of 4501 individuals in a meta-analysis of ﬁve
genome-wide association studies (GWASs) within ﬁve
cohorts (Table 1) with prospectively collected 25(OH)D
levels: a case–control study of lung cancer in the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study
(ATBC) (7); a case–control study of prostate cancer [Cancer
Genetic Markers of Susceptibility (CGEMS)] in the Prostate,
Lung, Colorectal, Ovarian Cancer Screening Trial (PLCO)
(8); three case–control studies of pancreatic cancer nested
within ATBC, Cancer Prevention Study-II (CPS-II) (9) and
Give Us a Clue to Cancer and Heart Disease Study (CLUE
II) (10); and case–control studies of breast cancer (CGEMS)
and type 2 diabetes (T2D) nested within the Nurses’ Health
Study (NHS) (11). Markers near genes known to be involved
in vitamin D synthesis or activation that showed strong evi-
dence for association with 25(OH)D levels in the GWAS
were genotyped in an additional 2221 individuals with serolo-
gic vitamin D levels from the case–control studies of colon
polyps and colorectal cancer nested in the NHS and a prostate
cancer case–control study nested within the Health Pro-
fessionals Follow-up Study (HPFS) (12–14).
RESULTS
A Manhattan plot of genetic signal for 25(OH)D levels shows
a genome-wide signiﬁcance for single-nucleotide polymorph-
isms (SNPs) on chromosome 4 (Fig. 1). In the region harbor-
ing the group-speciﬁc component gene (GC, encoding vitamin
D-binding protein, DBP) on chromosome 4q12-q13, a set of
SNPs were associated with circulating 25(OH)D levels at the
genome-wide signiﬁcance level. The strongest association



































































































































































































































































































































































































































































































































































































































































































































































































































































2740 Human Molecular Genetics, 2010, Vol. 19, No. 13Two additional SNPs in GC (rs7041 and rs1155563), in
moderate linkage disequilibrium (LD; r
2 ¼ 0.4; Supplemen-
tary Material, Fig. S1), reached the genome-wide signiﬁcance
in the GWAS data meta-analysis (P ¼ 4.1 × 10
222 and 3.5 ×
10
225, respectively). In the four-study pooled analysis (ATBC,
CPS-II, CLUE II and PLCO), we ﬁt the regression model
including all three genome-wide signiﬁcant SNPs in GC
along with the covariates used in the GWAS analysis and
observed the strongest association signal for rs2282679, with
much weaker signals from the other two SNPs (P ¼ 3.8 ×
10
24, 0.075 and 0.75 for rs2282679, rs7041 and rs1155563,
respectively). We also conducted a stratiﬁed analysis by con-
ditioning on genotype of rs2282679, and the two SNPs again
showed markedly weaker evidence for association after strati-
ﬁcation (P ¼ 0.002 and 0.027 for rs7041 and rs1155563,
respectively). Together, these observations suggest that the
three common variants confer an association signal derived
from a common source, with rs2282679 exhibiting the stron-
gest association with 25(OH)D levels. This association was
conﬁrmed in the pooled analysis of the replication studies
(P ¼ 5.4 × 10
221) and resulted in a ﬁnal combined
meta-analysis signiﬁcance of P ¼ 1.8 × 10
249. The difference
in mean 25(OH)D levels between carriers of two copies of the
minor allele versus those of none across the GWAS and repli-
cation studies ranged from 26.4 to 234.4% (median
218.3%; Table 2).
GC protein (DBP) is a serum glycoprotein that belongs to
the albumin family. It binds to 25(OH)D and other blood
vitamin D sterol metabolites and transports them in circulation
to target organs. It is plausible that rs2282679, in the intron 12,
located near the actin subdomain III (15), may differentially
affect GC binding of 25(OH)D (16). In previous candidate
gene studies, we (17) and others (18,19) reported that the
three GC SNPs were associated with circulating 25(OH)D
concentrations, with strongest P-values for rs2282679 (P ¼
10
23–10
25). Nonetheless, it is not clear whether the
25(OH)D concentration differentials by the number of GC
risk alleles also reﬂect differences in binding and bioavailabil-
ity of 25(OH)D, activated 1,25(OH)2D and other vitamin D
metabolites. On the basis of the pooled analysis of ATBC,
PLCO, CPS-II and CLUE II, compared with having the wild
type (AA), a heterozygote for the variant (C) has a nearly
2-fold higher risk (OR ¼ 1.83) of having clinically deﬁcient
25(OH)D levels (i.e. ,25 nmol/l). Under a linear-additive
genetic model for the square-root-transformed 25(OH)D
level, rs2282679 explains an additional 1.0% of the variance
after adjusting for other variables based on the pooled analysis
of GWAS and replication studies.
Although not reaching the genome-wide signiﬁcance, three
other SNPs in or near genes involved in vitamin D synthesis or
activation had P-values ,10
25 in the initial GWASs
(Table 2). In the 15th intron of NADSYN1 (chromosome
11q13.4; Supplementary Material, Fig. S2), which encode
nicotinamide adenine dinucleotide (NAD) synthetase-1,
rs3829251 was associated with 25(OH)D levels (P ¼ 8.8 ×
10
27) in the GWAS. NAD synthetase-1 catalyzes the ﬁnal
step in the biosynthesis of NAD, which involves a coenzyme
in common metabolic redox reactions and a substrate for
protein post-translational modiﬁcations (20). [A SNP in high
LD (r
2 ¼ 0.84–0.87) with rs3829251, rs1790349, located in
DHCR7, the gene encoding 7-dehydrocholesterol reductase,
an enzyme catalyzing the production in skin of cholesterol
from 7-dehydrocholesterol (21) using NADPH in 25(OH)D
de novo synthesis, was also associated with 25(OH)D concen-
trations (P ¼ 1.8 × 10
26). Because of the biological relevance
of DHCR7 to vitamin D metabolism, we subsequently refer to
the signal from this region as the ‘NADSYN1/DHCR7 locus’.]
The ﬁnding for the NADSYN1/DHCR7 locus was conﬁrmed in
our replication set (for rs11234027, r
2 ¼ 1.0 with rs3829251
in the HapMap CEU samples: P ¼ 1.0 × 10
23) and yielded
a combined genome-wide signiﬁcance of P ¼ 3.4 × 10
29.
The difference in mean 25(OH)D levels between homozygote
minor and homozygote major allele genotypes across the
GWASs ranged from 216.7 to 0% (median 22.4%) and
across replication studies from 27.3 to 224.9% (median
29.5%), and 1.2% of the variance in 25(OH)D concentrations
was accounted for by variation in this SNP across studies.
In the region harboring the open-reading frame 88
(C10orf88) on chromosome 10q26.13, two highly correlated
SNPs (r
2 ¼ 1) were associated with circulating 25(OH)D
levels in the GWAS [rs6599638 and rs1079458, with P ¼
3.3 × 10
27 and 1.8 × 10
26, respectively; (Table 2)]. The
role of this gene is not well-characterized, but these two
SNPs are located in the vicinity of ACADSB (acyl-coenzyme
A dehydrogenase), which is involved in cholesterol and
vitamin D synthesis. There were no notable associations
between SNPs in ACADSB and vitamin D concentrations,
however, and the association for rs6599638 was not conﬁrmed
in the pooled analysis of the replication studies (P ¼ 9.3 ×
10
21; meta-analysis with GWAS, P ¼ 2.4 × 10
25).
The variant rs2060793, located in the 5′ untranslated region
of the CYP2R1 gene encoding microsomal vitamin D
25-hydroxylase, was also associated with circulating
25(OH)D levels in the GWASs (P ¼ 1.4 × 10
25; Table 2).
Figure 1. Genome-wide associations of circulating 25-hydroxy vitamin D
graphed by chromosome position and 2log10 P-value based on the ﬁve
GWAS cohorts (n ¼ 4501). Only P values of .10
216 are plotted, with the
most signiﬁcant variants in the GC gene on chromosome 4 not being shown
(rs2282679, rs1155563 and rs7041; P-values of 1.96 × 10
230, 3.56 × 10
225
and 4.07 × 10
222, respectively).
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rs2282679 C (0.26) 4 72827247 GC Total 4.1 × 10
222 20.36 0.05
ATBC 1.5 × 10
28 42.1 37.2 35.2 20.38 0.07
CPS-II 0.09 60.1 57.4 46.0 20.31 0.18
CLUE II 2.2 × 10
23 67.5 58.4 44.3 20.69 0.22
PLCO 5.8 × 10
213 61.5 55.3 53.4 20.37 0.05
NHS-CGEMS 1.2 × 10
27 86.8 77.3 72.5 20.46 0.09
NHS-T2D 9.5 × 10
24 58.8 55.8 48.8 20.24 0.07
Replication studies Total 5.4 × 10
221 20.41 0.04
NHS-Polyps 3.4 × 10
25 70.5 65.5 57.5 20.35 0.09
NHS-CRC 2.2 × 10
26 71.5 67.3 56.3 20.42 0.09
HPFS 3.1 × 10
213 65.5 56.8 53.5 20.44 0.06
Combined meta-analysis 1.8 × 10
249 20.38 0.03
GWASs
rs3829251 A (0.19) 11 70872207 NADSYN1 Total 8.8 × 10
27 20.17 0.04
ATBC 2.0 × 10
22 41.4 38.8 39.4 20.14 0.06
CPS-II 0.75 61.1 64.9 61.0 0.07 0.21
CLUE II 0.60 56.2 61.7 46.8 0.16 0.30
PLCO 3.5 × 10
24 59.3 56.2 53.0 20.22 0.06
NHS-CGEMS 9.2 × 10
23 83.3 77.8 81.3 20.28 0.11
NHS-T2D 0.39 57.3 55.3 55.8 20.08 0.09
Replication studies
rs11234027
e A (0.16) 70911755 Total 1.0 × 10
23 20.19 0.06
NHS-Polyps 0.30 68.3 66.5 61.8 20.11 0.10
NHS-CRC 0.16 69.0 67.3 51.8 20.17 0.12
HPFS 1.7 × 10
23 62.0 57.3 57.5 20.25 0.08
Combined meta-analysis 3.4 × 10
29 20.18 0.03
GWASs
rs6599638 G (0.49) 10 124694139 C10orf88 Total 3.3 × 10
27 20.14 0.03
ATBC 5.0 × 10
24 41.8 39.6 39.5 20.19 0.06
CPS-II 0.95 57.3 58.4 56.8 20.01 0.16
CLUE II 0.11 65.6 61.8 58.0 20.33 0.20
PLCO 1.3 × 10
22 60.3 57.8 57.6 20.11 0.05
NHS-CGEMS 2.2 × 10
23 83.3 83.0 77.5 20.24 0.08
NHS-T2D 0.12 58.5 56.0 55.5 20.10 0.07
Replication Studies Total 9.3 × 10
21 0.00 0.04
NHS-Polyps 0.70 68.3 67.3 66.5 20.03 0.07
NHS-CRC 0.66 66.5 70.0 66.8 20.04 0.09
HPFS 0.55 60.5 60.3 61.3 0.03 0.06
Combined meta-analysis 2.4 × 10
25 20.09 0.04
GWASs
rs2060793 A (0.41) 11 14866810 CYP2R1 Total 1.4 × 10
25 0.12 0.03
ATBC 0.28 39.5 40.7 40.1 0.06 0.06
CPS-II 0.78 57.9 55.8 63.6 0.05 0.19
CLUE II 0.92 62.1 57.7 71.1 20.03 0.25
PLCO 0.15 57.1 59.1 58.6 0.07 0.05
NHS-CGEMS 3.5 × 10
24 77.0 83.3 80.5 0.28 0.08
NHS-T2D 8.9 × 10
24 53.8 58.0 59.3 0.22 0.07
Replication studies
rs1993116
e A (0.39) 14866810 Total 1.6 × 10
217 0.34 0.04
NHS-Polyps 6.2 × 10
29 62.5 68.8 75.0 0.39 0.07
NHS-CRC 5.2 × 10
24 65.5 68.8 73.8 0.29 0.08
HPFS 1.6 × 10
28 56.0 62.3 67.0 0.33 0.06
Combined meta-analysis 2.9 × 10
217 0.25 0.05
P-values for heterogeneity were .0.05, except for rs2060793 (P ¼ 0.01).
aSNP identiﬁer based on NCBI dbSNP.
bChromosomal location based on NCBI Human Genome Build 35 coordinates.
cThe result of 1 df test based on linear regression, using an additive model, after square-root transformation of 25(OH)D levels—adjusted for age, vitamin D assay
batch, study, case–control status, sex, body mass index, season of blood collection, vitamin D supplement intake, dietary vitamin D intake, region/latitude and
chosen eigenvectors to control population stratiﬁcation. The pooled P-value is based on the combined Wald statistics weighted by the square-root of the corresponding
sample size.
dSE: standard error; the regression b and standard error were based on square-root scale. The pooled b and standard error summary calculated based on the random-effect
model.
er
2 ¼ 1 in the HapMap CEU panel with the SNP from the initial GWAS.
2742 Human Molecular Genetics, 2010, Vol. 19, No. 13This SNP, located on chromosome 11p15.2, is in complete LD
(r
2 ¼ 1 in the HapMap CEU samples) with rs1993116 (Sup-
plementary Material, Fig. S3), which has been inconsistently
associated with 25(OH)D levels in the literature (22,23). We
conﬁrmed a signiﬁcant association between the latter SNP
and vitamin D levels (P ¼ 1.6 × 10
217) in our replication
sample and found a genome-wide signiﬁcance for the com-
bined studies from meta-analysis (P ¼ 2.9 × 10
217). The
difference in mean 25(OH)D levels between homozygote
minor and homozygote major allele genotypes across the
GWASs ranged from 1.5 to 14.4% (median 7.2%) and
across the replication studies from 12.7 to 20.0% (median
19.6%), but only 0.6% of the variance in 25(OH)D concen-
trations was accounted for by variation in this SNP.
The microsomal enzyme CYP2R1 catalyzes C-25 hydroxy-
lation of vitamin D3 to an active vitamin D receptor ligand in
the liver and other organs (24). An inherited mutation in this
genecausesthesubstitutionofaprolineforanevolutionarilycon-
served leucine at amino acid 99 in the CYP2R1 protein and the
proline to valine shift has been related to rickets (25), mediated
through this defect in vitamin D C-25 hydroxylation (24).
In combination, rs2282679 in GC, rs3829251 (rs11234027)
in the NADSYN1/DHCR7 locus, rs6599638 in C10orf88 and
rs2060793 (rs1993116) in CYP2R1 accounted for 2.8% of
the variance in circulating vitamin D levels, based on the esti-
mate in data pooled from ATBC, CPS-II, CLUE II and PLCO.
A sensitivity analysis of 1312 non-cancer case controls in
ATBC, CPS-II, CLUE II and PLCO gave similar b estimates
(Supplementary Material, Table S1). We also found a signiﬁ-
cant signal with clinical vitamin D deﬁciency [i.e. 25(OH)D
,25 nmol/l] for GC (one risk allele OR ¼ 1.83; P ¼ 2.5 ×
10
28), and weak or null associations for C10orf88 (OR 1.17;
P ¼ 8.1 × 10
22), NADSYN1/DHCR7 (OR 1.18; P ¼ 0.11)
and CYP2R1 (OR 0.89; P ¼ 0.21), based on 2907 subjects in
ATBC, PLCO, CPS-II and CLUE II (Supplementary Material,
Table S2). It should be noted, however, that the prevalence of
vitamin D deﬁciency in three of these four cohorts was very
low (i.e. 3–6%), and examination of the dichotomized
25(OH)D outcome reduced statistical power for this compari-
son. The odds ratio for clinical deﬁciency for having one
risk allele for each of the four gene loci was 2.97 (95% CI:
2.00–4.39), and the joint effect from the four loci is signiﬁcant
(P ¼ 3.2 × 10
28).
DISCUSSION
In this GWAS analysis, we found and replicated conclusive
evidence that variants in GC, the NADSYN1/DHCR7 locus
and CYP2R1 that encode the vitamin D carrier protein and
enzymes in the vitamin D metabolic pathway are associated
with circulating 25(OH)D levels, with the latter two genes
representing novel ﬁndings. An initial signal for C10orf88
(in the vicinity of ACADSB) was not replicated. The three
SNPs we found associated with vitamin D levels and with
clinical deﬁciency to some extent, along with nearby variants
in LD with them, could be included in studies of Mendelian
randomization of vitamin D status and disease outcomes,
although the modest differences by number of minor alleles
suggest that very large sample sizes would be needed to
conﬁrm the expected small associations. Strengths of the
study include its large sample size, with ﬁndings conﬁrmed
in multiple independent populations, and having the vitamin
D phenotype measured with good precision. Heterogeneity
was, however, observed for the 25(OH)D association with
CYP2R1. Potential limitations of our study include there
being only one blood sample assayed for 25(OH)D for each
person—measurements from multiple time points would
likely provide more valid estimates of usual circulating chole-
calciferol levels. Also, two laboratory methods were used to
determine 25(OH)D concentrations, and for the RIA method,
this was done for three separate parent studies, possibly contri-
buting to some of the cohort differences in the study ﬁndings.
Follow-up studies, as well as future meta-analyses in other
populations with GWAS that have measured 25(OH)D con-
centrations and possibly DBP, are likely to uncover more
common alleles associated with circulating plasma 25(OH)D
levels and vitamin D status.
Insights gained from the study of circulating vitamin D are
likely to have implications for the examination of complex
diseases such as osteoporosis, cardiovascular disease and
cancer. Further investigation of the biological mechanisms
underlying the associations observed here, and replication of
the ﬁndings in other populations, including those of African
and Asian descent, is required.
MATERIALS AND METHODS
We conducted a meta-analysis of ﬁve GWASs within ﬁve
cohorts (Table 1) with prospectively collected 25(OH)D
levels and replicated the ﬁndings in three prospective
case–control studies. Analyses were restricted to subjects of
European ancestry. The ﬁve GWASs were: a case–control
study of lung cancer in the Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study (ATBC) (7); a case–control study of
prostate cancer [Cancer Genetic Markers of Susceptibility
(CGEMS)] in the Prostate, Lung, Colorectal, Ovarian Cancer
Screening Trial (PLCO) (8); three case–control studies of
pancreatic cancer nested within ATBC, Cancer Prevention
Study-II (CPS-II) (9) and Give Us a Clue to Cancer and
Heart Disease Study (CLUE II) (10); and case–control
studies of breast cancer (CGEMS) and type 2 diabetes
(T2D) nested within the Nurses’ Health Study (NHS) (11).
GWAS genotyping used the Illumina 550K (or higher
version) platform with the exception of the T2D study,
which was genotyped using the Affymetrix 6.0 platform. Gen-
otypes for markers that were on the Illumina 550K platform
but not the Affymetrix 6.0 were imputed in the T2D study
using the hidden-Markov model algorithm implemented in
the MACH and the HapMap CEU reference panel (Rel 22).
Quality-control assessment of genotypes, including sample
completion and SNP call rates, concordance rates, deviation
from ﬁtness for the Hardy–Weinberg proportions in control
DNA and ﬁnal sample selection for association analyses, are
described elsewhere (26–29). For the majority (92%) of the
PLCO, ATBC, CPS-II and CLUE II samples, serum
25(OH)D concentrations were measured by competitive che-
miluminescence immunoassay (CLIA) in a single laboratory
(Heartland Assays, Ames, IA, USA) (30), with coefﬁcients
Human Molecular Genetics, 2010, Vol. 19, No. 13 2743of variation (CV) for 25(OH)D in the blinded duplicate
quality-control samples of 9.3% (intrabatch) and 12.7% (inter-
batch). Previously available 25(OH)D measurements for 492
ATBC subjects from other serologic substudies showed
similar CVs [9.5% (intrabatch) and 13.6% (interbatch)]. For
the NHS-CGEMS samples, plasma 25(OH)D levels were
measured by radioimmunoassay (RIA) (30) in three batches
(CVs 8.7–17.6%): two in the laboratory of Dr Michael
Holick at Boston University School of Medicine (31) and
the third in the laboratory of Dr Bruce Hollis at the Medical
University of South Carolina in Charleston, SC (31). Plasma
levels of 25(OH)D in the NHS-T2D samples were measured
in the Nutrition Evaluation Laboratory in the Human Nutrition
Research Center on Aging at Tufts University (with CV ¼
8.7%) by rapid extraction followed by an equilibrium I-125
RIA procedure (DiaSorin Inc., Stillwater, MN, USA) as speci-
ﬁed by the manufacturer’s procedural documentation and ana-
lyzed on a gamma counter (Cobra II, Packard).
Four markers selected for replication were genotyped by
TaqMan in three case–control samples: NHS colon polyp
study (13)( n ¼ 403/407 cases/controls), colorectal cancer
study (12) (173/371 cases/controls) and a study of prostate
cancer in the Health Professionals Follow-up Study (14)
(431/436 cases/controls). There was no overlap of participants
in the NHS-CGEMS, T2D, colon polyp or colorectal cancer
studies. Plasma 25(OH)D concentrations in these studies
were measured by RIA in the laboratory of Dr Bruce Hollis
[CVs 7.5, 11.8 and 5.4–5.6% (two-batch), respectively].
Concentrations of 25(OH)D were similar across CPS-II,
CLUE II and PLCO (Tables 1 and 2). In ATBC, the average
population concentration was lower, likely due to reduced
UVB solar radiation exposure at that northern latitude and
no blood collection during July and some of June and
August. The NHS had overall higher values, likely the result
of having had blood samples analyzed in a different laboratory
using a different assay. Nonetheless, there was a substantial
overlap with the observed range of 25(OH)D values across
all studies.
We conducted a pooled analysis (1) of four GWASs (ATBC,
CPS-II,CLUEIIandPLCO)andtestedtheassociation between
593 253 SNP markers that passed quality-control ﬁlters and the
square-root-transformed value of circulating 25(OH)D using
linear regression under an additive genetic model. We adjusted
for age, vitamin D assay batch, study, case–control status, sex,
body mass index (,20, 20–25, 25–30, 30+ kg/m
2), season
of blood collection (December–February; March–May;
June–August; September–November), vitamin D supplement
intake (missing, 0, 0–400 and 400+ IU/day), dietary vitamin
D intake (missing, ,100, 100–200, 200–300, 300–400 and
400+ IU/day), region/latitude and three eigenvectors to
control for population stratiﬁcation. Usual dietary intake and
other covariate information were collected through self-
administered food frequency questionnaires and baseline risk
factor questionnaires, respectively. The square-root transform-
ation was very close to the most optimal transformation ident-
iﬁed by the Box-Cox procedure and was used to ensure
normality of the residuals. The Wald test was used for testing
the association between each SNP and the outcome. A similar
approach was used for analysis of each of the following two
GWASs, NHS-CGEMS (2) and NHS-T2D (3). Imputed
markers in the NHS-T2D study were analyzed using genotype
dosages (expected allele counts). We conducted the meta-
analysis of the GWASs, and of the GWAS and replication
studies combined, by averaging the signed Wald statistics
weighted by the square root of the corresponding sample
sizes; this analysis is robustto differences in scale acrossdiffer-
ent techniques for measuring circulating 25(OH)D (32). We
also used the random-effect model to estimate the common
effect size and to assess heterogeneity among results from
different studies. The quantile–quantile plot of P-values from
the GWAS meta-analysis showed no evidence of systematic
type-I error inﬂation (lGC ¼ 1.0007; Fig. 2).
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